4 天前 - … first-line treatment for patients with advanced-stage disease. Early experiences
with tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR)-mutated and …

10 天前 - … for patients with EGFR exon 19 deletions or EGFR L858R … have challenged initial
treatment options and therapy … of combining earlier generation tyrosine kinase inhibitors (…

22 天前 - … treatment option. Hence, till date, wide surgical resection is considered to be the
reliable treatment … of development process, EGFR tyrosine kinase inhibitor resistance, MAPK …

25 天前 - … development of efficient EGFR tyrosine kinase inhibitors (… be used to treat advanced
NSCLC with common EGFR-… in the treatment of some uncommon mutations in the EGFR. [ …

29 天前 - … (EGFR)–mutated non–small cell lung cancer (NSCLC) post-treatment with first-
or second-generation EGFR tyrosine … mg of osimertinib as a treatment option for EGFR-mutated …

29 天前 - … EGFR enhances its tyrosine kinase activity by increasing the rates of EGF ligand
binding with EGFR… Although Gefitinib is not the first-line treatment of NSCLC without EGFR …

32 天前 - … Osimertinib, another EGFR-TKI, controlled his tumors for 9 months. Patient-derived …
to EGFR-TKIs. The findings suggest that EGFR-TKIs can be a potential treatment option for …

32 天前 - … Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of
resistance to EGFR tyrosine-kinase inhibitors. Cancer Manag Res. 2019;11:6343–51. …

34 天前 - … monotherapy with an EGFR tyrosine kinase inhibitor (TKI). Three generations of …
L718Q or G724S mutations following EGFR TKI treatment were identified; here, we describe …

34 天前 - … EGFR tyrosine kinase inhibitors (TKIs) are the recommended front-line option for
EGFR-… using EGFR-TKI treatment with ECOG status 0 or 1. Before enrollment in the study, the …